Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SAFESKIN -- Ignore unavailable to you. Want to Upgrade?

To: Mr. Happy who wrote (463)	11/22/1998 11:19:00 PM
From: W Shakespeare	Read Replies (1) \| Respond to of 828

If SFSK's competition can manufacturer large amounts of similar gloves, how will SFSK avoid either a loss of market share or a price war? The article was clear that such an event is a couple of years away, but I'm interested as to how the company plans to meet this challenge. Is a glove a glove? Or does SFSK have some kind of unique advantage over its competition?

To: Mr. Happy who wrote (463)	11/23/1998 8:16:00 AM
From: Beltropolis Boy	Read Replies (1) \| Respond to of 828

for the benefit of the board, a few details on the barron's article. ----- Safeskin Shares Could Fall More on Competition, Barron's Says Bloomberg News November 21, 1998, 1:53 p.m. PT San Diego, Nov. 21 (Bloomberg) -- Safeskin Corp.'s share price could fall further as the maker of disposable latex and synthetic gloves sees sales and profits eroded by growing competition, Barron's reported. New glove manufacturing factories planned by competitors and a shift away from latex to synthetic gloves caused prices to fall an average 5 percent in the past six months, Barron's quoted unidentified traders as saying. David Morash, Safeskin chief financial officer, said factories planned by competitors won't come on line for at least two years, and that higher inventories and accounts receivable that recently hurt cash flow at Safeskin were temporary. Safeskin shares fell 13 percent in late October after a Salomon Smith Barney analyst downgraded the stock to "neutral" from "buy" on concerns the company's sales growth would slow; yesterday, shares were unchanged at 22 7/16.